DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients. RA: What are the potentials of RLTs across cancer? JT: Cancer is an incredibly complex and heterogeneous disease, and, devastatingly, around 10… Read More
Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise… Read More
A large study has found that the risk of secondary blood cancers after CAR-T cell therapy is low, despite the Food and Drug Administration (FDA) warning. In November 2023, the FDA issued a warning about a risk of secondary cancers that may be associated with… Read More
A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More
A multispecific antibody candidate for B cell lymphoma preferentially engaged CD47 in presence of co-engagement of CD20 and CD19, in preclinical investigations. One dose of Nutcracker Therapeutics’ NTX-472 in vivo rapidly depleted B cells with no detectable binding to red blood cells. The results… Read More
A team of investigators at City of Hope in the US funded by the Prostate Cancer Foundation (PCF) reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor (CAR)-T cell therapy. The results of their first-in-human Phase I clinical trial, which… Read More
Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More
Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells,… Read More
OncoHost and Dana-Farber Cancer Institute have launched a new study to identify biomarkers for renal cell carcinoma (RCC). Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. The collaboration… Read More
With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More
Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. The combination therapy was also shown to reduce the risk of distant metastasis or… Read More
Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More
As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More
Phase II trial results have shown the superiority of immunotherapy pembrolizumab over chemotherapy when given before bowel cancer surgery. The results were presented by researchers at University College London (UCL) and UCLH at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. Read More
Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. The results of two ongoing Phase I/II clinical trials evaluating cancer immunotherapy epcoritamab, a T-cell engaging bispecific antibody, were shared at… Read More
